RATIONALE: Serotonin (5-HT) has been linked to impulsivity with recent data suggesting that different receptor sub-types exert opposing influences on this behaviour. OBJECTIVES: This work characterised the effects of 5-HT(2A) (ketanserin, (+/-)2,3-dimethoxyphenyl-1-[2-4-(piperidine)-methanol] [M100907]), 5-HT(2B) (6-chloro-5-methyl-1-(5-quinolylcarbamoyl) indoline [SB215505]) and 5-HT(2C) (6-chloro-5-methyl-1-[2-(2-methylpyridyl-3-oxy)-pyrid-5-yl carbomyl] indoline [SB242084]) receptor antagonists on impulsive behaviour, measured in the five-choice serial reaction time test (5CSRTT), in rats and mice. The effects of (+/-)-2,5-dimethoxy-4-iodoamphetamine (DOI) and (S)-2-(chloro-5-fluoro-indol-1-yl)-1-methylethylamine 1:1 C4H4O4 (Ro60-0175), two compounds that have been used extensively as agonists for the 5-HT(2A) and 5-HT(2C) receptor, were also measured. MATERIALS AND METHODS: Rats and mice were trained on the 5CSRTT in which reinforcement is earned for detecting and correctly responding to brief presentations of a stimulus light. Impulsivity in this task is measured as premature responding, before stimulus presentation. Several variants of the task were used in which the inter-trial interval (ITI) length was manipulated to alter basal levels of premature responding. RESULTS: In the rat, ketanserin and M100907 reduced and SB242084 enhanced premature responding. SB215505 had no effect. DOI generally disrupted responding, while Ro60-0175 reduced premature responding when a long ITI was used. In mice, M100907 reduced and SB242084 increased premature responding when the ITI was lengthened. The effects of these drugs on other aspects of performance were less robust. M100907 and ketanserin did not affect response accuracy but tended to slow speed of responding; SB242084 occasionally increased speed of responding and slightly reduced accuracy. CONCLUSIONS: Serotonin exerts both excitatory and inhibitory influences on motor impulsivity via 5-HT(2A) and 5-HT(2C) receptors in both rats and mice.
RATIONALE: Serotonin (5-HT) has been linked to impulsivity with recent data suggesting that different receptor sub-types exert opposing influences on this behaviour. OBJECTIVES: This work characterised the effects of 5-HT(2A) (ketanserin, (+/-)2,3-dimethoxyphenyl-1-[2-4-(piperidine)-methanol] [M100907]), 5-HT(2B) (6-chloro-5-methyl-1-(5-quinolylcarbamoyl) indoline [SB215505]) and 5-HT(2C) (6-chloro-5-methyl-1-[2-(2-methylpyridyl-3-oxy)-pyrid-5-yl carbomyl] indoline [SB242084]) receptor antagonists on impulsive behaviour, measured in the five-choice serial reaction time test (5CSRTT), in rats and mice. The effects of (+/-)-2,5-dimethoxy-4-iodoamphetamine (DOI) and (S)-2-(chloro-5-fluoro-indol-1-yl)-1-methylethylamine 1:1 C4H4O4 (Ro60-0175), two compounds that have been used extensively as agonists for the 5-HT(2A) and 5-HT(2C) receptor, were also measured. MATERIALS AND METHODS:Rats and mice were trained on the 5CSRTT in which reinforcement is earned for detecting and correctly responding to brief presentations of a stimulus light. Impulsivity in this task is measured as premature responding, before stimulus presentation. Several variants of the task were used in which the inter-trial interval (ITI) length was manipulated to alter basal levels of premature responding. RESULTS: In the rat, ketanserin and M100907 reduced and SB242084 enhanced premature responding. SB215505 had no effect. DOI generally disrupted responding, while Ro60-0175 reduced premature responding when a long ITI was used. In mice, M100907 reduced and SB242084 increased premature responding when the ITI was lengthened. The effects of these drugs on other aspects of performance were less robust. M100907 and ketanserin did not affect response accuracy but tended to slow speed of responding; SB242084 occasionally increased speed of responding and slightly reduced accuracy. CONCLUSIONS:Serotonin exerts both excitatory and inhibitory influences on motor impulsivity via 5-HT(2A) and 5-HT(2C) receptors in both rats and mice.
Authors: J R Martin; M Bös; F Jenck; J Moreau; V Mutel; A J Sleight; J Wichmann; J S Andrews; H H Berendsen; C L Broekkamp; G S Ruigt; C Köhler; A M Delft Journal: J Pharmacol Exp Ther Date: 1998-08 Impact factor: 4.030
Authors: T Koskinen; S Ruotsalainen; T Puumala; R Lappalainen; E Koivisto; P T Männistö; J Sirviö Journal: Neuropharmacology Date: 2000-01-28 Impact factor: 5.250
Authors: G A Kennett; M D Wood; F Bright; J Cilia; D C Piper; T Gager; D Thomas; G S Baxter; I T Forbes; P Ham; T P Blackburn Journal: Br J Pharmacol Date: 1996-02 Impact factor: 8.739
Authors: Philippe De Deurwaerdère; Sylvia Navailles; Kelly A Berg; William P Clarke; Umberto Spampinato Journal: J Neurosci Date: 2004-03-31 Impact factor: 6.167
Authors: Latham H L Fink; Noelle C Anastasio; Robert G Fox; Kenner C Rice; F Gerard Moeller; Kathryn A Cunningham Journal: Neuropsychopharmacology Date: 2015-02-10 Impact factor: 7.853
Authors: Peter J McLaughlin; Julia E Jagielo-Miller; Emily S Plyler; Kerry K Schutte; V Kiran Vemuri; Alexandros Makriyannis Journal: Psychopharmacology (Berl) Date: 2017-02-01 Impact factor: 4.530
Authors: Andrzej Jakubczyk; Anna Klimkiewicz; Maciej Kopera; Aleksandra Krasowska; Małgorzata Wrzosek; Halina Matsumoto; Margit Burmeister; Kirk J Brower; Marcin Wojnar Journal: J Psychiatr Res Date: 2013-01-12 Impact factor: 4.791